BackAspen Pharmacare Holdings Overview

Aspen Pharmacare Holdings Total Liabilities

Track Aspen Pharmacare Holdings's total liabilities ($28B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$27.68B
45.72% YoYΔ $-23.32B vs prior year quarter

Peer trimmed avg / median

Loading

Aspen Pharmacare Holdings Total Liabilities History

Loading

Aspen Pharmacare Holdings vs. peers: Total Liabilities Comparison

Loading

Aspen Pharmacare Holdings Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Aspen Pharmacare Holdings (APNHY) FAQ

Aspen Pharmacare Holdings posts a total liabilities of $28B as of June 2026. That compares with $51B in the prior-year period — down 45.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Aspen Pharmacare Holdings's total liabilities was $51B. The latest reading is $28B — a 45.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Aspen Pharmacare Holdings's financial statement story. At $28B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for APNHY's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Aspen Pharmacare Holdings's other metric pages and overview cover the third.

Judging Aspen Pharmacare Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $28B here, then scan peer and history charts to see if the gap is persistent.